Danaher Reports Second Quarter 2025 Financial Results

Details

The company reported net earnings of $555 million, or $0.77 per diluted common share, with non-GAAP adjusted diluted net earnings per common share at $1.80. Revenues increased by 3.5% year-over-year to $5.9 billion, while non-GAAP core revenue increased by 1.5% year-over-year. Operating cash flow was $1.3 billion, and non-GAAP free cash flow was $1.1 billion. For the full year 2025, Danaher expects non-GAAP core revenue to grow approximately 3% year-over-year and has increased its full-year adjusted diluted net earnings per common share guidance to a range of $7.70 to $7.80.

Items reported

Exhibits (1)

About Danaher Corporation

Danaher Corporation is a globally recognized science and technology company specializing in the development, design, and manufacturing of diverse industrial and healthcare products. With a primary focus on innovations in diagnostics, life sciences, dental, and environmental and applied solutions, Danaher serves a multitude of industries and market sectors. Its cutting-edge diagnostic equipment aids medical professionals in delivering precise healthcare, while its life sciences tools and technologies propel biomedical research and development. The company's environmental solutions also play a key role in enhancing water quality analysis and management. Headquartered in Washington, D.C., Danaher is renowned for its strong operational culture exemplified by the Danaher Business System (DBS), which emphasizes continuous improvement and sustainable innovation. This approach has solidified Danaher's presence and influence in both developing specialized solutions and improving efficiency across global markets. The company's strategic acquisitions and consistent focus on innovation have positioned it as a leader in delivering essential solutions that drive significant improvements for healthcare, research, and industrial clients.